TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms BRAVERY TR
- 11 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 02 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Mar 2018 New trial record